Adam Thompson-Harvey1, Mahi Yetukuri2, Alec R Hansen2, Matthew C Simpson3, Eric Adjei Boakye4, Mark A Varvares5, Nosayaba Osazuwa-Peters3,6. 1. Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin. 2. Saint Louis University School of Medicine, St. Louis, Missouri. 3. Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, St. Louis, Missouri. 4. Department of Population Science and Policy, Southern Illinois University School of Medicine, Springfield, Illinois. 5. Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts. 6. Saint Louis University Cancer Center, St. Louis, Missouri.
Abstract
BACKGROUND: The current study was conducted to determine whether the incidence of late-stage head and neck cancer (HNC) is decreasing and to estimate the risk of late-stage HNC diagnosis based on race and sex. METHODS: Age-adjusted incidence rates for patients aged ≥18 years with stage IV HNC were abstracted from the Surveillance, Epidemiology, and End Results database (2004-2015). Rates were stratified by race, sex, and age. Joinpoint regression estimated annual percent changes (APCs) in rates over time, and logistic regression estimated adjusted odds ratios (aORs). RESULTS: There were 57,118 patients with stage IV HNC in the current study cohort, with an average age of 61.9 years. From 2004 to 2015, the age-adjusted incidence rates for stage IV HNC significantly increased by 26.1% (6.11 per 100,000 person-years in 2004 to 7.70 per 100,000 person-years in 2015). White and Asian/Pacific Islander/American Indian/Alaska Native patients had significant increases in incidence (APC for white patients, 3.03 [P < .01] and APC for other races, 1.95 [P < .01]), whereas rates among black patients remained stable but were highest across racial groups. Incidence was higher among males compared with females. When restricted only to patients with stage IVC (metastatic) HNC, there remained a significant increase in incidence, especially for oropharyngeal cancer, which showed a 22.9% increase (0.21 per 100,000 person-years in 2004 vs 0.25 per 100,000 person-years in 2015). Despite a decreasing overall incidence of stage IV HNC in black patients (aOR, 1.28; 95% CI, 1.22-1.34) they, along with males (aOR, 3.95; 95% CI, 3.80-4.11), had significantly increased risks of being diagnosed with late-stage HNC. CONCLUSIONS: There is an increasing incidence of late-stage HNC in the United States, with male patients and black individuals faring the worst.
BACKGROUND: The current study was conducted to determine whether the incidence of late-stage head and neck cancer (HNC) is decreasing and to estimate the risk of late-stage HNC diagnosis based on race and sex. METHODS: Age-adjusted incidence rates for patients aged ≥18 years with stage IV HNC were abstracted from the Surveillance, Epidemiology, and End Results database (2004-2015). Rates were stratified by race, sex, and age. Joinpoint regression estimated annual percent changes (APCs) in rates over time, and logistic regression estimated adjusted odds ratios (aORs). RESULTS: There were 57,118 patients with stage IV HNC in the current study cohort, with an average age of 61.9 years. From 2004 to 2015, the age-adjusted incidence rates for stage IV HNC significantly increased by 26.1% (6.11 per 100,000 person-years in 2004 to 7.70 per 100,000 person-years in 2015). White and Asian/Pacific Islander/American Indian/Alaska Native patients had significant increases in incidence (APC for white patients, 3.03 [P < .01] and APC for other races, 1.95 [P < .01]), whereas rates among black patients remained stable but were highest across racial groups. Incidence was higher among males compared with females. When restricted only to patients with stage IVC (metastatic) HNC, there remained a significant increase in incidence, especially for oropharyngeal cancer, which showed a 22.9% increase (0.21 per 100,000 person-years in 2004 vs 0.25 per 100,000 person-years in 2015). Despite a decreasing overall incidence of stage IV HNC in black patients (aOR, 1.28; 95% CI, 1.22-1.34) they, along with males (aOR, 3.95; 95% CI, 3.80-4.11), had significantly increased risks of being diagnosed with late-stage HNC. CONCLUSIONS: There is an increasing incidence of late-stage HNC in the United States, with male patients and black individuals faring the worst.
Keywords:
Epidemiology; Joinpoint regression analysis; Surveillance; and End Results (SEER); annual percent change (APC); head and neck cancer (HNC); incidence trends; late-stage presentation
Authors: Amy Y Spurlock; Teresa W Johnson; Ali Pritchett; Leah Pierce; Jenna Hussey; Kelly Johnson; Holly Carter; Stephen L Davidson; Manpreet S Mundi; Lisa Epp; Ryan T Hurt Journal: Nutr Clin Pract Date: 2021-08-31 Impact factor: 3.204
Authors: Neil E Bhola; Christian Njatcha; Lanlin Hu; Eliot D Lee; Jamie V Shiah; Mi-Ok Kim; Daniel E Johnson; Jennifer R Grandis Journal: Head Neck Date: 2021-08-03 Impact factor: 3.147
Authors: Jenny L Ren; Raniv D Rojo; Joy Vanessa D Perez; Sai-Ching J Yeung; Ehab Y Hanna; Cielito C Reyes-Gibby Journal: BMC Cancer Date: 2021-12-06 Impact factor: 4.430
Authors: Amy L Shaver; Katia Noyes; Heather M Ochs-Balcom; Gregory Wilding; Andrew D Ray; Sung Jun Ma; Mark Farrugia; Anurag K Singh; Mary E Platek Journal: Cancers (Basel) Date: 2021-08-25 Impact factor: 6.639